Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (C26 tumor-bearing mice) with ex vivo tissue analyses.
PubMed 31150737 · doi:10.1016/j.jmb.2019.05.032
What was done
Researchers evaluated the effects of autophagy modulation on muscle wasting in C26 tumor-bearing mice. Interventions included inhibiting autophagy via beclin-1 knockdown, promoting autophagy via TP53INP2/DOR overexpression, and treating mice with the beta-2 agonist formoterol. Assessed outcomes included muscle mass, muscle morphology, autophagy markers and flux, atrogene expression, mitochondrial dynamics-related gene expression, and ex vivo muscle fiber respiration.
What was found
The abstract reports directional outcomes without exact numbers or statistical metrics. In C26 tumor-bearing mice, beclin-1 knockdown failed to rescue muscle loss and exacerbated abnormal muscle morphology. Stimulating autophagy via TP53INP2 overexpression exacerbated muscle atrophy, induced atrogene expression, and suppressed mitochondrial dynamics genes. Conversely, formoterol spared muscle mass while reducing static autophagy markers without impairing autophagy flux. Ex vivo muscle fiber respiration was reduced in tumor-bearing mice, indicating tumor-induced mitochondrial dysfunction.
Why it matters
These findings suggest that balanced autophagy is required for muscle maintenance in cancer cachexia, as both unbridled autophagy induction and complete autophagy inhibition exacerbate muscle pathology.
Limits
The study was conducted entirely in a rodent model (C26 tumor-bearing mice) and ex vivo muscle preparations; translational relevance to human cancer cachexia is unproven. The abstract does not report animal sample sizes (n), numerical effect sizes, dispersion measures, or p-values.
Cited by
- supports Cellular autophagy is elevated in certain cancers and muscle-wasting diseases.